Insider Buying: Leap Therapeutics, Inc. (LPTX) COO Acquires $6,441,813.21 in Stock
Leap Therapeutics, Inc. (NASDAQ:LPTX) COO Augustine Lawlor acquired 1,057,769 shares of the stock in a transaction that occurred on Tuesday, November 14th. The stock was purchased at an average cost of $6.09 per share, with a total value of $6,441,813.21. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Leap Therapeutics, Inc. (LPTX) opened at $7.21 on Friday. Leap Therapeutics, Inc. has a fifty-two week low of $4.90 and a fifty-two week high of $10.10.
Leap Therapeutics (NASDAQ:LPTX) last posted its earnings results on Monday, November 13th. The company reported ($0.73) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.11). analysts expect that Leap Therapeutics, Inc. will post -3.15 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Insider Buying: Leap Therapeutics, Inc. (LPTX) COO Acquires $6,441,813.21 in Stock” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.thecerbatgem.com/2017/11/19/insider-buying-leap-therapeutics-inc-lptx-coo-acquires-6441813-21-in-stock.html.
Separately, Zacks Investment Research lowered Leap Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th.
A hedge fund recently bought a new stake in Leap Therapeutics stock. Renaissance Technologies LLC bought a new stake in shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 45,445 shares of the company’s stock, valued at approximately $417,000. Renaissance Technologies LLC owned about 0.48% of Leap Therapeutics at the end of the most recent quarter. Institutional investors own 0.81% of the company’s stock.
About Leap Therapeutics
Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).
Receive News & Stock Ratings for Leap Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics Inc. and related stocks with our FREE daily email newsletter.